Method for Treating Blood, Blood Products and Organs

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes methods for treating blood, blood products, and organs ex vivo (outside the body) to remove or detoxify amyloid-beta oligomers, which are implicated in Alzheimer's disease and other amyloid-related conditions. The invention uses specially designed peptides, polymers, antibodies, and hybrid molecules that selectively bind to and deactivate amyloid-beta oligomers. These agents can be immobilized on carriers (such as beads, membranes, or filters) or used in dialysis systems to purify donor blood, blood products, or transplanted organs before use, thereby preventing transmission or progression of amyloid-related diseases.

Use CasesContent extracted from patent full text and abstract with AI.

• Preparing and purifying blood or blood products in blood banks before transfusion to reduce the risk of transmitting amyloid-related diseases such as Alzheimer's.
• Treating organs ex vivo prior to transplantation to remove amyloid-beta oligomers, reducing the risk of transferring neurodegenerative disease pathology to recipients.
• Applying the technology for preventative blood cleaning in individuals at risk, potentially delaying or preventing onset of amyloid-based diseases.
• Using standardized kits and procedures for hospitals and transfusion services to routinely test and treat blood products for pathogenic amyloid oligomers.
• Developing diagnostic assays for early detection and quantification of amyloid-beta oligomers in biological samples for research or clinical use.
• Extending the method to other amyloid-related disorders such as Parkinson's disease, Creutzfeldt-Jakob disease, BSE, and certain forms of diabetes where amyloid fragments may contribute to disease.

BenefitsContent extracted from patent full text and abstract with AI.

• Reduces risk of transmitting Alzheimer's and similar diseases via blood transfusion or organ transplantation by removing toxic amyloid-beta oligomers.
• Provides a method for preventative treatment of blood and organs, potentially lowering incidence of neurodegenerative disease in recipients.
• Offers versatile application, as the method can be adapted to a variety of ex vivo purification technologies (filters, beads, dialysis, etc.).
• Utilizes highly specific and stable peptide and polymer agents, which have high affinity and selectivity for amyloid-beta oligomers, making the purification more effective and reliable.
• Can also detoxify and permanently neutralize the pathogenic oligomers, not just remove them, minimizing residual disease risk.
• Supports early diagnostic procedures and quantitative assays for amyloid-related pathology, improving disease screening and management.
• Provides innovations that function across multiple amyloid diseases, enabling broad utility in clinical transfusion and transplantation medicine.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The invention relates to the treatment of blood, blood products and organs for the removal and/or detoxification of amyloid-beta oligomers.